O	0	5	Value
O	6	8	of
O	9	13	post
O	13	14	-
O	14	23	operative
O	24	36	reassessment
O	37	39	of
O	40	48	estrogen
O	49	57	receptor
O	58	59	α
O	60	70	expression
O	71	80	following
O	81	92	neoadjuvant
O	93	105	chemotherapy
O	106	110	with
O	111	113	or
O	114	121	without
B-intervention	122	131	gefitinib
O	132	135	for
O	136	144	estrogen
O	145	153	receptor
O	154	162	negative
O	163	169	breast
O	170	176	cancer
O	176	177	.

O	178	181	The
O	182	186	NICE
O	187	192	trial
O	193	196	was
O	197	205	designed
O	206	208	to
O	209	217	evaluate
O	218	221	the
O	222	230	possible
O	231	239	benefits
O	240	242	of
O	243	249	adding
O	250	259	epidermal
O	260	266	growth
O	267	273	factor
O	274	282	receptor
O	283	291	targeted
O	292	299	therapy
O	300	302	to
O	303	314	neoadjuvant
O	315	327	chemotherapy
O	328	330	in
O	331	339	patients
O	340	344	with
O	345	353	estrogen
O	354	362	receptor
O	363	364	α
O	365	366	(
O	366	368	ER
O	368	369	)
O	370	378	negative
O	379	382	and
O	383	391	operable
O	392	398	breast
O	399	405	cancer
O	405	406	.

O	407	418	Preclinical
O	419	423	data
O	424	428	have
O	429	438	suggested
O	439	443	that
O	444	454	signalling
O	455	462	through
O	463	466	the
O	467	471	ErbB
O	472	481	receptors
O	482	484	or
O	485	495	downstream
O	496	505	effectors
O	506	509	may
O	510	517	repress
O	518	520	ER
O	521	531	expression
O	531	532	.

O	533	537	Here
O	538	541	the
O	542	549	authors
O	550	562	investigated
O	563	570	whether
O	571	580	gefitinib
O	580	581	,
O	582	587	given
O	588	599	neoadjuvant
O	600	602	in
O	603	614	combination
O	615	619	with
O	620	630	epirubicin
O	631	634	and
O	635	651	cyclophosphamide
O	652	653	(
O	653	655	EC
O	655	656	)
O	656	657	,
O	658	663	could
O	664	671	restore
O	672	674	ER
O	675	685	expression
O	685	686	.

O	687	695	Eligible
O	696	704	patients
O	705	707	in
O	708	711	the
O	712	716	NICE
O	717	722	trial
O	723	727	were
B-eligibility	728	733	women
I-eligibility	734	738	with
I-eligibility	739	749	unilateral
I-eligibility	749	750	,
I-eligibility	751	758	primary
I-eligibility	759	767	operable
I-eligibility	767	768	,
I-eligibility	769	771	ER
I-eligibility	772	780	negative
I-eligibility	781	789	invasive
I-eligibility	790	796	breast
I-eligibility	797	803	cancer
I-eligibility	804	805	≥
I-eligibility	806	807	2
I-eligibility	808	810	cm
O	810	811	.

O	812	820	Material
O	821	825	from
O	826	834	patients
O	835	845	randomized
O	846	849	and
O	850	860	completing
O	861	870	treatment
O	871	872	(
O	872	876	four
O	877	883	cycles
O	884	886	of
O	887	898	neoadjuvant
O	899	901	EC
O	902	906	plus
O	907	909	12
O	910	915	weeks
O	916	918	of
O	919	925	either
O	926	935	gefitinib
O	936	938	or
O	939	946	placebo
O	946	947	)
O	948	950	in
O	951	954	the
O	955	959	NICE
O	960	965	trial
O	966	972	having
O	973	982	available
O	983	985	ER
O	986	992	status
O	993	997	both
O	998	1000	at
O	1001	1009	baseline
O	1010	1013	and
O	1014	1019	after
O	1020	1031	neoadjuvant
O	1032	1041	treatment
O	1042	1046	were
O	1047	1055	eligible
O	1056	1059	for
O	1060	1064	this
O	1065	1070	study
O	1070	1071	.

O	1072	1078	Tumors
O	1079	1083	with
O	1084	1094	indication
O	1095	1097	of
O	1098	1105	changed
O	1106	1108	ER
O	1109	1118	phenotype
O	1119	1120	(
O	1120	1125	based
O	1126	1128	on
O	1129	1138	collected
O	1139	1148	pathology
O	1149	1156	reports
O	1156	1157	)
O	1158	1162	were
O	1163	1184	immunohistochemically
O	1185	1195	reassessed
O	1196	1205	centrally
O	1205	1206	.

B-total-participants	1207	1210	115
O	1211	1219	patients
O	1220	1224	were
O	1225	1233	eligible
O	1234	1237	for
O	1238	1242	this
O	1243	1248	study
O	1248	1249	;
B-intervention-participants	1250	1252	59
O	1253	1261	patients
O	1262	1264	in
O	1265	1268	the
O	1269	1278	gefitinib
O	1279	1284	group
O	1285	1288	and
B-control-participants	1289	1291	56
O	1292	1300	patients
O	1301	1303	in
O	1304	1307	the
B-control	1308	1315	placebo
O	1316	1321	group
O	1321	1322	.

O	1323	1327	Five
O	1328	1329	(
O	1329	1330	4
O	1330	1331	.
O	1331	1332	3
O	1332	1333	%
O	1333	1334	)
O	1335	1337	of
O	1338	1341	115
O	1342	1348	tumors
O	1349	1356	changed
O	1357	1359	ER
O	1360	1369	phenotype
O	1370	1374	from
O	1375	1383	negative
O	1384	1386	to
O	1387	1395	positive
O	1395	1396	.

O	1397	1398	A
B-outcome	1399	1405	change
I-outcome	1406	1409	was
I-outcome	1410	1414	seen
O	1415	1417	in
B-iv-bin-abs	1418	1423	three
O	1424	1432	patients
O	1433	1435	in
O	1436	1439	the
O	1440	1449	gefitinib
O	1450	1451	(
B-iv-bin-percent	1451	1452	5
I-iv-bin-percent	1452	1453	.
I-iv-bin-percent	1453	1454	1
I-iv-bin-percent	1454	1455	%
O	1455	1456	)
O	1457	1460	and
O	1461	1463	in
B-cv-bin-abs	1464	1467	two
O	1468	1476	patients
O	1477	1479	in
O	1480	1483	the
O	1484	1491	placebo
O	1492	1493	(
B-cv-bin-percent	1493	1494	3
I-cv-bin-percent	1494	1495	.
I-cv-bin-percent	1495	1496	6
I-cv-bin-percent	1496	1497	%
O	1497	1498	)
O	1499	1504	group
O	1505	1509	with
O	1510	1511	a
O	1512	1522	difference
O	1523	1525	of
O	1526	1527	1
O	1527	1528	.
O	1528	1530	51
O	1530	1531	%
O	1532	1533	(
O	1533	1535	95
O	1535	1536	%
O	1537	1539	CI
O	1539	1540	,
O	1541	1542	-
O	1542	1543	6
O	1543	1544	.
O	1544	1545	1
O	1545	1546	-
O	1546	1547	9
O	1547	1548	.
O	1548	1549	1
O	1549	1550	)
O	1550	1551	.

O	1552	1559	Results
O	1560	1562	of
O	1563	1566	the
O	1567	1571	NICE
O	1572	1577	trial
O	1578	1582	have
O	1583	1587	been
O	1588	1596	reported
O	1597	1607	previously
O	1607	1608	.

O	1609	1613	Post
O	1613	1614	-
O	1614	1623	operative
O	1624	1636	reassessment
O	1637	1639	of
O	1640	1642	ER
O	1643	1653	expression
O	1654	1661	changed
O	1662	1665	the
O	1666	1676	assessment
O	1677	1679	of
O	1680	1682	ER
O	1683	1689	status
O	1690	1692	in
O	1693	1694	a
O	1695	1700	small
O	1701	1704	but
O	1705	1716	significant
O	1717	1725	fraction
O	1726	1728	of
O	1729	1737	patients
O	1738	1741	and
O	1742	1748	should
O	1748	1749	,
O	1750	1758	whenever
O	1759	1767	possible
O	1767	1768	,
O	1769	1771	be
O	1772	1781	performed
O	1782	1791	following
O	1792	1803	neoadjuvant
O	1804	1816	chemotherapy
O	1817	1820	for
O	1821	1823	ER
O	1824	1832	negative
O	1833	1839	breast
O	1840	1846	cancer
O	1846	1847	.

O	1848	1857	Gefitinib
O	1858	1861	did
O	1862	1865	not
O	1866	1872	affect
O	1873	1876	the
O	1877	1886	reversion
O	1887	1891	rate
O	1892	1894	of
O	1895	1897	ER
O	1898	1906	negative
O	1907	1913	tumors
O	1913	1914	.
